Post-ASH 2023 ALL Highlights

Featuring presentations & discussions on selected ALL abstracts from the 65^th ASH Annual Meeting

30 Jan 2024 | 8-10:30am CST / 2-4:30pm GMT / 3-5:30pm CET

Please note that this webinar has passed – the recordings will be available on VJHemOnc soon

Chair: Bijal Shah | Moderators: Sabina Chiaretti, Nicola Gökbuget

*Please note: This webinar is for HCPs and allied health professionals only.
Your application to attend will be reviewed and confirmed by VJHemOnc.

Draft Agenda

8:00-8:55am CST

Session 1: CAR-T & Bispecifics

1. Real-World Outcomes of Brexu-Cel for R/R B-ALL: CIBMTR Registry Evidence – 1029 – Evandro Bezerra
2. Brexu-Cel in Adults with R/R B-ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) – 1030 – Gregory Roloff
3. Obe-Cel, (AUTO1) for R/R Adult B-ALL. Pooled Analysis of the Ongoing FELIX Phase Ib/II Study – 222 – Claire Roddie
4. Sequential Chemo and Blina to Improve MRD in Adult Ph- B-ALL. Final Results of the Phase II Gimema LAL2317 Trial – 826 – Sabina Chiaretti
5. Dose Reduced Chemo in Sequence with Blina for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-ALL: Preliminary Results of GMALL Bold – 964 – Nicola Gökbuget

Live Q&A

8:55-9:35am

Session 2: Transplant & TKIs

6. Moderate Incidence but Striking Correlation with TBI of Secondary Malignancies after HSCT in Children with ALL: Long-Term Follow-up from the Prospective International BFM- and Forum-Trials – 110 – Anita Lawitschka
7. Infusion of UM171-Expanded Cord Blood Led to Excellent Survival in Patients with High-Risk Leukemias: Results from Two Independent Phase II Studies – 1040 – Filippo Milano
8. Phase I Study of Asciminib (ABL001) Plus Dasatinib and Prednisone for BCR-ABL1-Positive ALL and Blast Phase CML in Adults – 965 – Marlise Luskin

Live Q&A

9:35-10:20am

Session 3: T-ALL

9. Frontline Consolidation with Nelarabine for Adults with High-Risk T-ALL. Results of the Graall-2014/T Atriall Phase 2 Study – 962 – Nicolas Boissel
10. Nelarabine (NEL), Pegylated Asparginase (PEG) and Venetoclax (VEN) Incorporated to HCVAD Chemotherapy in the Frontline Treatment of Adult Patients with T-ALL/Lymphoblastic Lymphoma (T-ALL/T-LBL) – 963 – Jayatsu Senapati
11. NGS-Based Stratification Refines the Risk Stratification in T-ALL and Identifies a Very High-Risk Subgroup of Patients – 844 – Mathieu Simonin
12. Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in R/R T-ALL/ LBL – 770 – Armin Ghobadi

Live Q&A

10:30am CST | End of webinar

The Post-ASH 2023 ALL Highlights has been supported by: